Supplementary Materials
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Kagan L, Turner MR, Balu-Iyer SV, Mager DE. Subcutaneous absorption of monoclonal antibodies:
role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats.
Pharmaceutical Research. 2012;29(2):490-499.
Fischer SK, Yang J, Anand B, Cowan K, Hendricks R, Li J, Nakamura G, Song A. The assay design
used for measurement of therapeutic antibody concentrations can affect pharmacokinetic
parameters: Case studies. MAbs. 2012;4(5):623-631.
Kelley SK, Gelzleichter T, Xie D, Lee WP, Darbonne WC, Qureshi F, Kissler K, Oflazoglu E, Grewal
IS. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40
antibody (SGN-40) in rodents and non-human primates. British Journal of Pharmacology.
2006;148(8):1116-1123.
Everitt DE, Davis CB, Thompson K, DiCicco R, Ilson B, Demuth SG, Herzyk DJ, Jorkasky DK. The
pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized
monoclonal antibody to respiratory syncytial virus, in healthy volunteers. The Journal of
Infectious Diseases. 1996;174(3):463-469.
Fisher RG, Johnson JE, Dillon SB, Parker RA, Graham BS. Prophylaxis with respiratory syncytial
virus F-specific humanized monoclonal antibody delays and moderately suppresses the native
antibody response but does not impair immunity to late rechallenge. The Journal of Infectious
Diseases. 1999;180(3):708-713.
Davis CB, Hepburn TW, Urbanski JJ, Kwok DC, Hart TK, Herzyk DJ, Demuth SG, Leland M, Rhodes
GR. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped
human monoclonal antibody RSHZ19. Drug Metabolism and Disposition. 1995;23(10):1028-1036.
Wu F, Tamhane M, Morris ME. Pharmacokinetics, lymph node uptake, and mechanistic PK
model of near-infrared dye-labeled bevacizumab after IV and SC administration in mice. The
AAPS Journal. 2012;14(2):252-261.
Meyer CH, Krohne TU, Holz FG. Intraocular pharmacokinetics after a single intravitreal injection
of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina. 2011;31(9):1877-1884.
Wu B, Johnson J, Soto M, Ponce M, Calamba D, Sun YN. Investigation of the mechanism of
clearance of AMG 386, a selective angiopoietin-1/2 neutralizing peptibody, in splenectomized,
nephrectomized, and FcRn knockout rodent models. Pharmaceutical Research. 2012;29(4):10571065.
Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D,
Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS. Safety, pharmacokinetics, and antitumor
activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid
tumors. Journal of Clinical Oncology. 2009;27(21):3557-3565.
Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune
WJ, Zhong J, Cai W, Freimuth W. Biologic activity and safety of belimumab, a neutralizing anti-Blymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic
lupus erythematosus. Arthritis Research & Therapy. 2008;10(5):R109.
Halpern WG, Lappin P, Zanardi T, Cai W, Corcoran M, Zhong J, Baker KP. Chronic administration
of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte
populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic
effects. Toxicological Sciences. 2006;91(2):586-599.
Vugmeyster Y, Allen S, Szklut P, Bree A, Ryan M, Ma M, Spaulding V, Young D, Guay H, Bloom L,
Leach MW, O'Toole M, Adkins K. Correlation of pharmacodynamic activity, pharmacokinetics,
and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV
administration to cynomolgus monkeys. Journal of Translational Medicine. 2010;8:41.
14.
15.
16.
17.
18.
19.
20.
21.
22.
Vugmeyster Y, Guay H, Szklut P, Qian MD, Jin M, Widom A, Spaulding V, Bennett F, Lowe L,
Andreyeva T, Lowe D, Lane S, Thom G, Valge-Archer V, Gill D, Young D, Bloom L. In vitro potency,
pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a
mouse model of lupus. MAbs. 2010;2(3):335-346.
Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB. Preclinical
pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal
antibody against vascular endothelial growth factor. The Journal of Pharmacology and
Experimental Therapeutics. 1999;288(1):371-378.
Gordon MS, Margolin K, Talpaz M, Sledge GW, Jr., Holmgren E, Benjamin R, Stalter S, Shak S,
Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular
endothelial growth factor in patients with advanced cancer. Journal of Clinical Oncology.
2001;19(3):843-850.
Chakraborty A, Tannenbaum S, Rordorf C, Lowe PJ, Floch D, Gram H, Roy S. Pharmacokinetic and
pharmacodynamic properties of canakinumab, a human anti-interleukin-1beta monoclonal
antibody. Clinical Pharmacokinetics. 2012;51(6):e1-18.
Benincosa LJ, Chow FS, Tobia LP, Kwok DC, Davis CB, Jusko WJ. Pharmacokinetics and
pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.
The Journal of Pharmacology and Experimental Therapeutics. 2000;292(2):810-816.
Chow FS, Benincosa LJ, Sheth SB, Wilson D, Davis CB, Minthorn EA, Jusko WJ. Pharmacokinetic
and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans.
Clinical Pharmacology and Therapeutics. 2002;71(4):235-245.
Kakkar T, Ma M, Zhuang Y, Patton A, Hu Z, Mounho B. Pharmacokinetics and safety of a fully
human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys. Pharmaceutical
Research. 2007;24(10):1910-1918.
Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S,
Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR. Targeted MET inhibition in
castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with
rilotumumab plus mitoxantrone and prednisone. Clinical Cancer Research. 2013;19(1):215-224.
Vugmeyster Y, Szklut P, Tchistiakova L, Abraham W, Kasaian M, Xu X. Preclinical
pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL13 antibodies with different IL-13 neutralization mechanisms. International
Immunopharmacology. 2008;8(3):477-483.
ADAPT-5 code for mPBPK model (human prediction):
**********************************************************************
C
ADAPT
*
C
Version 5
*
C**********************************************************************
C
*
C
MODEL
*
C
*
C
This file contains Fortran subroutines into which the user
*
C
must enter the relevant model equations and constants.
*
C
Consult the User's Guide for details concerning the format for
*
C
entered equations and definition of symbols.
*
C
*
C
1. Symbol- Parameter symbols and model constants
*
C
2. DiffEq- System differential equations
*
C
3. Output- System output equations
*
C
4. Varmod- Error variance model equations
*
C
5. Covmod- Covariate model equations (ITS,MLEM)
*
C
6. Popinit- Population parameter initial values (ITS,MLEM)
*
C
7. Prior - Parameter mean and covariance values (ID,NPD,STS) *
C
8. Sparam- Secondary parameters
*
C
9. Amat - System state matrix
*
C
*
C**********************************************************************
C######################################################################C
Subroutine SYMBOL
Implicit None
Include 'globals.inc'
Include 'model.inc'
CC
C----------------------------------------------------------------------C
C
Enter as Indicated
C
C----c-----------------------------------------------------------------C
NDEqs
NSParam
NVparam
NSecPar
NSecOut
Ieqsol
Descr
= 4
! Enter # of Diff. Eqs.
= 5
! Enter # of System Parameters.
= 2
! Enter # of Variance Parameters.
= 0
! Enter # of Secondary Parameters.
= 0 ! Enter # of Secondary Outputs (not used).
= 1 ! Model type: 1 - DIFFEQ, 2 - AMAT, 3 - OUTPUT only.
= ' mPBPK Model human PK prediction'
CC
C----------------------------------------------------------------------C
C
Enter Symbol for Each System Parameter (eg. Psym(1)='Kel')
C
C----c-----------------------------------------------------------------C
Psym(1)='sigma_1'
Psym(2)='sigma_2'
Psym(3)='Kp'
Psym(4)='a1'
Psym(5)='m1'
CC
C----------------------------------------------------------------------C
C
Enter Symbol for Each Variance Parameter {eg: PVsym(1)='Sigma'}
C
C----c-----------------------------------------------------------------C
PVsym(1)='intercept'
PVsym(2)='Slope'
CC
C----------------------------------------------------------------------C
C
Enter Symbol for Each Secondary Parameter {eg: PSsym(1)='CLt'}
C
C----c-----------------------------------------------------------------C
C----------------------------------------------------------------------C
C----------------------------------------------------------------------C
C
Return
End
C######################################################################C
Subroutine DIFFEQ(T,X,XP)
Implicit None
Include 'globals.inc'
Include 'model.inc'
Real*8 T,X(MaxNDE),XP(MaxNDE),sigma_1,Kp,CLp,ISF,Vp,L
Real*8 sigma_2,VL,sigmaL,a1,m1
CC
C----------------------------------------------------------------------C
C
Enter Differential Equations Below {e.g. XP(1) = -P(1)*X(1) }
C
C----c-----------------------------------------------------------------C
ISF = 18.2-2.6
Vp = 2.6
L = 2.9/24
VL = 5.2
sigmaL = 0.2
sigma_1 = P(1)
sigma_2 = P(2)
Kp = P(3)
a1 = P(4)
m1 = P(5)
CLp=a1*70**m1
if (P(1) .GT. 1 .OR. P(2) .GT. 1) Then
XP(1)=0
Else
c
c
XP(1)= R(1)-X(1)/Vp*(CLp+0.33*L*(1-sigma_1)+ 0.67*L*(1-sigma_2))
+ X(4)*(L/VL)
Endif
XP(2)= X(1)/Vp*(0.33*L)*(1-sigma_1)
- X(2)/(0.65*ISF*Kp)*(0.33*L)*(1-sigmaL)
XP(3)= X(1)/Vp*(0.67*L)*(1-sigma_2)
- X(3)/(0.35*ISF*Kp)*(0.67*L)*(1-sigmaL)
XP(4)=X(2)/(0.65*ISF*Kp)*(0.33*L)*(1-sigmaL) + X(3)/(0.35*ISF*Kp)
C *(0.67*L)*(1-sigmaL) - X(4)*(L/VL)
c
C----------------------------------------------------------------------C
C----------------------------------------------------------------------C
C
Return
End
C######################################################################C
Subroutine OUTPUT(Y,T,X)
Implicit None
Include 'globals.inc'
Include 'model.inc'
Real*8 Y(MaxNOE),T,X(MaxNDE),Vp
CC
C----------------------------------------------------------------------C
C
Enter Output Equations Below
{e.g. Y(1) = X(1)/P(2) }
C
C----c-----------------------------------------------------------------C
Vp = 2.6
Y(1) = X(1)/Vp
C----------------------------------------------------------------------C
C----------------------------------------------------------------------C
C
Return
End
C######################################################################C
Subroutine VARMOD(V,T,X,Y)
Implicit None
Include 'globals.inc'
Include 'model.inc'
Real*8 V(MaxNOE),T,X(MaxNDE),Y(MaxNOE)
CC
C----------------------------------------------------------------------C
C
Enter Variance Model Equations Below
C
C
{e.g. V(1) = (PV(1) + PV(2)*Y(1))**2 }
C
C----c-----------------------------------------------------------------C
V(1) = (PV(1) + PV(2)*Y(1))**2
C----------------------------------------------------------------------C
C----------------------------------------------------------------------C
C
Return
End
C######################################################################C
C
Subroutine COVMOD(Pmean, ICmean, PC)
Defines any covariate model equations (MLEM, ITS)
Implicit None
Include 'globals.inc'
Include 'model.inc'
Real*8 PC(MaxNCP)
Real*8 Pmean(MaxNSP+MaxNDE), ICmean(MaxNDE)
CC
C----------------------------------------------------------------------C
C
Enter # of Covariate Parameters
C
C----c-----------------------------------------------------------------C
NCparam = 0
! Enter # of Covariate Parameters.
CC
C----------------------------------------------------------------------C
C
Enter Symbol for Covariate Params {eg: PCsym(1)='CLRenal'}
C
C----c-----------------------------------------------------------------C
CC
C----------------------------------------------------------------------C
C
For the Model Params. that Depend on Covariates Enter the Equation C
C
{e.g. Pmean(1) = PC(1)*R(2) }
C
C----c-----------------------------------------------------------------C
C----------------------------------------------------------------------C
C----------------------------------------------------------------------C
C
Return
End
C######################################################################C
C
Subroutine POPINIT(PmeanI,ICmeanI,PcovI,ICcovI, PCI)
Initial parameter values for population program parameters (ITS, MLEM)
Implicit None
Include 'globals.inc'
Include 'model.inc'
Integer I,J
Real*8 PmeanI(MaxNSP+MaxNDE), ICmeanI(MaxNDE)
Real*8 PcovI(MaxNSP+MaxNDE,MaxNSP+MaxNDE), ICcovI(MaxNDE,MaxNDE)
Real*8 PCI(MaxNCP)
CC
C----------------------------------------------------------------------C
C Enter Initial Values for Population Means
C
C
{ e.g. PmeanI(1) = 10.0
}
C
C----c-----------------------------------------------------------------C
CC
C----------------------------------------------------------------------C
C
Enter Initial Values for Pop. Covariance Matrix (Lower Triang.)
C
C
{ e.g. PcovI(2,1) = 0.25
}
C
C----c-----------------------------------------------------------------C
CC
C----------------------------------------------------------------------C
C
Enter Values for Covariate Model Parameters
C
C
{ e.g. PCI(1) = 2.0
}
C
C----c-----------------------------------------------------------------C
C----------------------------------------------------------------------C
C----------------------------------------------------------------------C
C
Return
End
C######################################################################C
C
Subroutine PRIOR(Pmean,Pcov,ICmean,ICcov)
Parameter mean and covariance values for MAP estimation (ID,NPD,STS)
Implicit None
Include 'globals.inc'
Include 'model.inc'
Integer I,J
Real*8 Pmean(MaxNSP+MaxNDE), ICmean(MaxNDE)
Real*8 Pcov(MaxNSP+MaxNDE,MaxNSP+MaxNDE), ICcov(MaxNDE,MaxNDE)
CC
C----------------------------------------------------------------------C
C Enter Nonzero Elements of Prior Mean Vector
C
C
{ e.g. Pmean(1) = 10.0
}
C
C----c-----------------------------------------------------------------C
CC
C----------------------------------------------------------------------C
C
Enter Nonzero Elements of Covariance Matrix (Lower Triang.)
C
C
{ e.g. Pcov(2,1) = 0.25
}
C
C----c-----------------------------------------------------------------C
C----------------------------------------------------------------------C
C----------------------------------------------------------------------C
C
Return
End
C######################################################################C
Subroutine SPARAM(PS,P,IC)
Implicit None
Include 'globals.inc'
Real*8 PS(MaxNSECP), P(MaxNSP+MaxNDE), IC(MaxNDE)
CC
C----------------------------------------------------------------------C
C
Enter Equations Defining Secondary Paramters
C
C
{ e.g. PS(1) = P(1)*P(2)
}
C
C----c-----------------------------------------------------------------C
C----------------------------------------------------------------------C
C----------------------------------------------------------------------C
C
Return
End
C######################################################################C
Subroutine AMAT(A)
Implicit None
Include 'globals.inc'
Include 'model.inc'
Integer I,J
Real*8 A(MaxNDE,MaxNDE)
DO I=1,Ndeqs
Do J=1,Ndeqs
A(I,J)=0.0D0
End Do
End Do
CC
C----------------------------------------------------------------------C
C
Enter non zero elements of state matrix {e.g. A(1,1) = -P(1) }
C
C----c-----------------------------------------------------------------C
C----------------------------------------------------------------------C
C----------------------------------------------------------------------C
C
Return
End
C######################################################################C
Phoenix code for mPBPK model (human):
MODEL
remark ******************************************************
remark This code is for mPBPK with allometric scaling
remark ******************************************************
COMMANDS
NFUNCTIONS 1
NDERIVATIVES 4
NPARAMETERS 4
PNAMES 'sigma1','sigma2','a', 'm'
NCONS 1
NSECO 0
END
TEMPORARY
T=X
Dose = CON(1)
ISF = 18.2 - 2.6
Vp = 2.6
L = 2.9/24
VL = 5.2
Kp = 0.8
CLp= a1*70**m1
Duration = 1
IF T>Duration THEN
Rinf = 0
ELSE
Rinf = Dose/Duration
ENDIF
END
START
Z(1)=0
Z(2)=0
Z(3)=0
Z(4)=0
END
DIFFERENTIAL
IF sigma1 > 1 THEN
DZ(1) = 0
ELSE
DZ(1)= Rinf -Z(1)/Vp*(CLp+0.33*L*(1-sigma1)+ 0.67*L*(1-sigma2))+ Z(4)*(L/VL)
ENDIF
IF sigma2 >1 THEN
DZ(1) = 0
ELSE
DZ(1)= Rinf -Z(1)/Vp*(CLp+0.33*L*(1-sigma1)+ 0.67*L*(1-sigma2))+ Z(4)*(L/VL)
ENDIF
DZ(2)= Z(1)/Vp*(0.33*L)*(1-sigma1) - Z(2)/(0.65*ISF*Kp)*(0.33*L)*0.8
DZ(3)= Z(1)/Vp*(0.67*L)*(1-sigma2) - Z(3)/(0.35*ISF*Kp)*(0.67*L)*0.8
DZ(4)= Z(2)/(0.65*ISF*Kp)*(0.33*L)*0.8 + Z(3)/(0.35*ISF*Kp)*(0.67*L)*0.8 - Z(4)*(L/VL)
END
FUNCTION 1
F=Z(1)/2.6
END
EOM